Clients could realize reduced cost and time to market by using firm for all stages of production.

DSM Pharmaceuticals reports the expansion of its service offerings to include formulation development and clinical trial manufacturing (CTM) for solid dosage form products.


“This expansion of services will have significant value-added benefits to our customers in terms of reducing cost and accelerating time to market as they will be able to avoid the high cost of tech transfers required for commercial launch by conducting development, CTM, and commercial manufacturing all at DSM’s Greenville, NC, facilities,” remarks Terry Novak, president and business unit director.


DSM’s pharmaceutical development services will now include preformulation, analytical development, stability studies, formulation and reformulation development, controlled and modified release, controlled substances, clinical trial supply, and regulatory support.

Previous articleNeuropsychiatrie, Decouverte & Innovation Collaborates with Genizon on Schizophrenia Research
Next articleAntipsychotic from Otsuka and Bristol-Myers Squibb Wins Label Expansion